Author

S. Khoo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

C. G. Banda· 1 shared C. Hartley· 1 shared D. G. Lalloo· 1 shared D. J. Terlouw· 1 shared F. K. Dzinjalamala· 1 shared H. Goldswain· 1 shared I. Donovan-Banfield· 1 shared J. A. Hiscox· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

C. G. Banda

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Antiviral activity of molnupiravir precursor NHC against SARS-CoV-2 Variants of Concern (VOCs) and implications for the therapeutic window and resistance

T. Prince, I. Donovan-Banfield, H. Goldswain, R. Penrice-Randal, C. Hartley, T. Fletcher, S. Khoo, J. A. Hiscox

This study evaluates the antiviral activity of molnupiravir's active metabolite NHC against SARS-CoV-2 variants, finds no resistance after 20 passages, and suggests earlier administration for better efficacy.

bioRxiv · Nov 23, 2021 · PreprintMicrobiology

Impact of efavirenz, ritonavir-boosted lopinavir and nevirapine based antiretroviral regimens on the pharmacokinetics of lumefantrine and safety of artemether-lumefantrine in falciparum-negative HIV-infected Malawian adults stabilized on antiretroviral therapy

C. G. Banda, F. K. Dzinjalamala, M. Mukaka, J. Mallewa, V. Maiden, D. J. Terlouw, D. G. Lalloo, S. Khoo, V. Mwapasa

This study evaluates how different antiretroviral therapies affect lumefantrine pharmacokinetics and the safety of artemether-lumefantrine in HIV-infected adults, finding significant variations in lumefantrine exposure and safety profiles.

bioRxiv · Jun 3, 2018Pharmacology & Toxicology